It is the mission of Isogenis to become the provider of the most widely used and cost-effective immune modulating therapeutics that will revolutionize treatment of immune disorders, genetic diseases, and transplant tolerance.

Isogenis will produce immunosuppressive drugs based on its technology, validate the efficiency of these products in pre-clinical models, develop and produce the therapeutics for human use, perform their clinical testing, obtain regulatory approval, and market these therapeutics.